Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
SPDR S&P Pharmaceuticals ETF XPH
$41.41
-$0.59 (-1.44%)
На 18:01, 12 мая 2023
Ключевые показатели
-
Marketcap
230296305.00000000
-
week52high
44.84
-
week52low
37.94
-
Revenue
-
P/E TTM
-
Beta
0.00000000
-
EPS
2.77803350
-
Last Dividend
0.60600000
-
Next Earnings Date
07 мая 2023 г. в 01:46
Описание компании
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Pharma ETFs Gain Post Q1 Earnings
Zacks Investment Research
09 мая 2023 г. в 13:01
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Zacks Investment Research
21 апр 2023 г. в 07:39
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals
Seeking Alpha
04 апр 2023 г. в 23:52
XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Zacks Investment Research
15 мар 2023 г. в 07:41
Smart Beta ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Zacks Investment Research
13 янв 2023 г. в 07:32
Smart Beta ETF report for XPH